Zhenyang Development's Merger and Acquisition Rumors: 68% Discounted Valuation, Mismatched Core Business, Vague Synergies, and Lack of Relief for Small and Medium Shareholders

Ask AI · What risks are hidden behind the 68% valuation discount in the development of Zhenyang?

Blue Whale News, April 3rd: Zhenyang Development (603213) announced that on April 1, 2026, it received the Shanghai Stock Exchange’s “Inquiry Letter on the Review of the Application for Share Swap and Merger by Absorption of Zhejiang Huhang Yong Expressway Co., Ltd. with Zhejiang Zhenyang Development Co., Ltd. and Related Party Transactions” (Shanghai Stock Review (Mergers & Acquisitions) [2026] No. 20), raising review questions on the compliance, transaction arrangements, valuation reasonableness, industry competition, related-party transactions, and other matters of this transaction.

On April 1, 2026, Zhenyang Development received the review inquiry letter from the SSE regarding the share swap and merger plan with Zhejiang Huhang Yong, raising multiple doubts about the transaction scheme. As a rare recent case of a Hong Kong-listed company swapping shares to acquire an A-share company, this deal, launched in August 2025, has attracted widespread market attention. Regulatory focus has centered on valuation reasonableness, the feasibility of integration amid ongoing performance decline, the authenticity of synergy effects, and the impact of the transaction structure on the rights of minority shareholders.

The valuation basis lacks sufficient market reference, and the share swap ratio shows subjective bias.

The inquiry letter emphasizes the process and reasonableness of determining the 1:1.08 share swap ratio. According to the disclosed plan, this ratio was negotiated based on the issuance price of Zhejiang Huhang Yong A-shares and the market price of Zhenyang Development’s stock, but no comparable transaction cases, industry valuation multiples, or third-party valuation reports were provided. Zhejiang Huhang Yong is a Hong Kong-listed company whose Hong Kong stock price has been at a long-term discount; before the plan announcement on September 3, 2025, the average of the last 30 trading days was 4.28 HKD per share, approximately 3.92 RMB; meanwhile, Zhenyang Development’s A-share closing price during the same period was 13.42 RMB, with a significant valuation gap. Under this context, each share of Zhenyang Development exchanges for only 1.08 shares of Zhejiang Huhang Yong’s new A-shares, implying that each Zhenyang Development share is valued at about 4.23 RMB, nearly 68.4% below its market price at that time. The company responded that this ratio considered historical share price performance, business complementarity, and future synergy expectations, but did not quantify the discount, nor clarified whether an independent financial advisor was involved to assess the fairness of the share swap price, making it difficult to dispel market doubts about the fairness of the pricing.

Performance continues to decline, yet major asset restructuring is pushed forward, with integration risks significantly underestimated.

The inquiry letter points out that Zhenyang Development’s net profit attributable to parent in 2024 was 191 million RMB, down 23.21% year-on-year; for the first half of 2025, estimated net profit was between 45 million and 53 million RMB, a decrease of 50.41% to 57.89% year-on-year; the actual net profit in the first half of 2025 was 50.63 million RMB, down 52.63%. Meanwhile, the company’s chlor-alkali main business was affected by weak downstream demand and large price fluctuations in caustic soda and PVC. Although revenue in the first half of 2025 reached 1.34B RMB, gross profit margin was not disclosed; the profit decline far exceeded revenue growth, indicating ongoing deterioration in profitability. Facing significant operational pressure, the company still chose to terminate listing and cancel legal entity status, transferring all assets, liabilities, and personnel into Zhejiang Huhang Yong’s system. The company responded that “this transaction is conducive to optimizing resource allocation and enhancing risk resistance,” but did not provide any quantitative analysis of how the chemical sector would integrate into the highway and securities dual-main business structure, nor disclosed whether Zhejiang Huhang Yong has management experience, technical reserves, or risk control capabilities in the chemical industry. Conversely, multiple media outlets cited industry insiders pointing out that highway business is highly regulated with low volatility, whereas chlor-alkali chemicals are cyclical, energy-intensive, and environmentally constrained, with fundamental differences in financial modeling, capital expenditure pace, safety, and compliance requirements. Simple consolidation could exacerbate overall performance volatility.

The so-called “synergy effects” lack substantive support; hydrogen energy and photovoltaic materials are empty concepts.

The inquiry letter questions whether the repeatedly mentioned “transportation energy ecosystem,” “hydrogen storage and transportation,” and “photovoltaic materials” in the transaction announcement have a realistic basis. Data shows that Zhenyang Development’s main business is caustic soda, chlorine, hydrochloric acid, liquid chlorine, and other basic chlor-alkali products, with over 95% of its 2024 revenue of 2.9B RMB coming from these traditional chemicals; Zhejiang Huhang Yong’s core assets are highways such as Huhang Yong Expressway and Shangsan Expressway, and its controlling stake in Zhejiang Merchants Securities, with no chemical technology R&D platform, hydrogen energy demonstration projects, or photovoltaic auxiliary material production capacity. Although the company claims “accelerating the group’s development in hydrogen storage and transportation, photovoltaic materials, and other infrastructure fields,” as of October 2025, Zhenyang Development had only signed a framework strategic cooperation agreement with Ningbo Graphene Innovation Center, which did not specify any financial amount, nor did it include concrete technology transfer paths, industrialization timelines, or funding plans. Notably, this innovation center is indirectly held by related parties of Zhenyang Development with a 15.31% stake, making the cooperation a related-party transaction, and there is no empirical evidence that its scientific achievements can be integrated into Zhejiang Huhang Yong’s existing infrastructure network. The company’s response still describes such unimplemented collaborations as “having formed a preliminary basis for synergy,” which may overstate the transaction logic.

The “A+H” listing plan masks financing motives, with structural flaws in dual-platform financing capacity.

The inquiry letter questions Zhejiang Huhang Yong’s true intention behind the “A+H” dual listing via this merger. The plan states that “it will help broaden funding sources and support highway construction,” but Zhejiang Huhang Yong’s 2025 interim financial report has not been disclosed, and its Hong Kong financing capacity shows no signs of improvement—average daily trading volume in Hong Kong in 2025 was less than HKD 100M, with long-term liquidity issues. In contrast, Zhenyang Development’s market value before suspension on September 3, 2025, was about 6.8 billion RMB, with active A-share trading and more accessible refinancing channels. After the transaction, Zhejiang Huhang Yong plans to list the newly issued A-shares and existing domestic shares on the Shanghai Stock Exchange’s main board, which could theoretically improve its domestic financing convenience. However, the company did not disclose the scale of its A-share issuance, the use of raised funds, or subsequent capital operations, only vaguely stating “to supplement operating funds and optimize debt structure.” Considering Zhejiang Huhang Yong’s subsidiary Zhejiang Merchants Securities’ net profit of about 1.23 billion RMB in 2024 and stable cash flow from highway operations, it has no urgent need for refinancing; in contrast, Zhenyang Development’s net cash flow from operating activities in the first half of 2025 was negative 107 million RMB, increasing short-term debt repayment pressure. This merger objectively provides its controlling shareholder Zhejiang Transportation Group with a convenient path to divest inefficient chemical assets and access A-share financing. The company’s response avoided analyzing the financing motive, only emphasizing “aligning with the strategic support of the state-owned economy,” failing to address core regulatory concerns about whether the transaction deviates from main business or involves disguised fund-raising.

Disputing shareholders lack cash exit options and have no effective remedy mechanisms.

Weak exit mechanisms for minority shareholders and virtually no enforcement measures. The inquiry letter specifically points out that this share swap and merger did not set a cash option for dissenting shareholders, nor clarified how dissenting shareholders can exercise rights, the reporting procedures, or settlement timelines. According to the “Administrative Measures for Major Asset Restructuring of Listed Companies,” sufficient safeguards should be provided for major restructurings involving public shareholders’ rights. The plan only states that “dissenting shareholders of Zhenyang Development may submit written requests before the general meeting, which the board will review to decide whether to provide compensation,” without mandatory cash buyout obligations or third-party valuation mechanisms. In this context, the lack of an effective exit mechanism will further weaken minority shareholders’ bargaining power. The company responded that “it has ensured shareholders’ rights to information and voting through the shareholder meeting procedures,” but did not make specific commitments on practical remedies for dissenting shareholders, nor disclosed potential litigation risks or regulatory penalties.